Biomarker Guided CNI Substitution in Kidney Transplantation
生物标志物引导肾移植中的 CNI 替代
基本信息
- 批准号:9926399
- 负责人:
- 金额:$ 20.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-17 至 2021-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAdverse eventAftercareAllograftingAntibodiesAntibody FormationB cell differentiationB-LymphocytesBiological MarkersBiopsyCalcineurin inhibitorCategoriesCellsChronicClinicalClinical TrialsComplementDataDiagnostic testsEnrollmentExclusion CriteriaFOXP3 geneFailureFibrosisGenerationsGoalsGraft RejectionGrantHLA-DR AntigensHumanImmuneImmune responseImmunosuppressionIndividualInflammationInflammatoryInflammatory ResponseInjuryInstitutional Review BoardsInterleukin-6InterventionKidney TransplantationLinkMaintenanceMediatingMediator of activation proteinMolecularMonitorMonoclonal AntibodiesMonoclonal Antibody TherapyMycophenolateNatural ImmunityObservational StudyOutcomePathogenicityPathway interactionsPatient-Focused OutcomesPatientsPharmaceutical PreparationsPhenotypePlasma CellsPlasmablastPositioning AttributePrednisonePrognostic MarkerProtocols documentationRandomized Controlled TrialsRegulatory T-LymphocyteRenal functionReperfusion InjuryResolutionRiskRisk stratificationSafetyStatistical Data InterpretationT cell differentiationT-LymphocyteTestingTherapeutic AgentsTherapeutic immunosuppressionTimeTransplant RecipientsTransplantationTreatment ProtocolsValidationWithdrawalWorkadaptive immunityarmbaseclinical riskcohortcytokinedesigndiagnostic biomarkerexperienceimprovedimproved outcomeisoimmunitymTOR Inhibitornoninvasive diagnosisnovel markernovel therapeuticsoperationpost-transplantpredictive markerprogramsprospectiverecruitresponseside effectstandard of caresubcutaneousvalidation studies
项目摘要
Abstract
Kidney transplant recipients have suboptimal long-term outcomes on current therapy predominantly due to off-
target effects of calcineurin inhibitor (CNI)-based protocols, and/or their failure to control the immune response
to the graft. Improving patient outcomes will require novel therapeutic agents that inhibit components of the
recipient’s immune response not controlled by CNI-based therapy. Interleukin (IL)-6 is a cytokine that promotes
T cell proinflammatory phenotypes (i.e. Tfh, Th1, Th17 cells) while inhibiting regulatory T cells, as well as
promoting antibody formation by inducing B cell differentiation into plasmablasts. The critical involvement of IL-
6 in these pathways makes it an attractive target for attempts to improve kidney transplant outcomes, especially
in the context of CNI substitution strategies. Additionally, while CNI withdrawal/substitution can improve kidney
function, randomized controlled trials of CNI withdrawal/substitution performed by our group and others, in
clinically “low risk” kidney transplant recipients have failed. Thus, current clinical risk stratification strategies and
available immunosuppressive therapies are inadequate for guiding individualized immunosuppression. The co-
PIs of this proposal have identified that the level of HLA-DR/DQ molecular mismatch (mMM): a) classifies kidney
transplant recipients as high, intermediate or low risk for developing a primary alloimmune response (i.e.
rejection), and b) identifies the low-risk category as those likely to tolerate CNI minimization/withdrawal. Based
on these data the FDA accepted HLA-DR/DQ mMM into its Biomarker Qualification Program with the caveat
that prospective multicenter validation is required. To this end, we propose a prospective observational,
multicenter, HLA mMM validation study (Aim 1) that includes, in a subset of 300 immune quiescence patients,
a randomized controlled trial substituting anti-IL-6 mAb (Clazakizumab [Claza]) for CNI (Aim 2), testing the
impact of the intervention on 2 year outcomes. Mechanistic studies will delineate the pathways by which Claza
impacts outcomes after CNI substitution. Within this framework, we will test the hypothesis that in the absence
of pre-existing DSA, the HLA-DR/DQ mMM score is both a prognostic and predictive biomarker capable of
guiding immunosuppressive therapy in kidney transplantation. In addition, our consortium has identified multiple
non-invasive diagnostic biomarkers of subclinical/clinical rejection. In Aim 3 we will: a) validate the utility of each
biomarker alone and together as non-invasive diagnostic tests for detect rejection in a real-world kidney
transplant cohort, and b) assess the utility of each biomarker to detect resolution of rejection in response to
therapy as determined by a post-treatment biopsy. The goal of this R34 proposal is to complete the study
protocol design, finish designing the mechanistic studies, finalize the statistical analysis plan, and establish the
framework for trial operation and management in order to be in a position to submit an FDA trial IND application,
a final application for IRB approval and a U01 application.
摘要
肾移植受者在目前的治疗中具有次优的长期结局,主要是由于非-
基于钙调磷酸酶抑制剂(CNI)的方案的靶向作用,和/或其未能控制免疫应答
移植物改善患者的预后将需要新的治疗剂,其抑制肿瘤细胞的组分。
受体的免疫反应不受基于CNI的治疗控制。白细胞介素(IL)-6是一种细胞因子,
T细胞促炎表型(即Tfh、Th 1、Th 17细胞),同时抑制调节性T细胞,以及
通过诱导B细胞分化成浆母细胞来促进抗体形成。IL的关键参与-
6在这些途径中的作用使其成为试图改善肾移植结果的有吸引力的靶点,
在CNI替代策略的背景下。此外,虽然CNI停药/替代可以改善肾脏
功能,随机对照试验CNI撤出/替代由我们的小组和其他人,
临床上“低风险”的肾移植接受者失败了。因此,目前的临床风险分层策略和
现有的免疫抑制疗法不足以指导个体化的免疫抑制。该公司-
本提案的PI已经确定HLA-DR/DQ分子错配(mMM)水平:a)将肾脏分类为
移植受者为发展原发性同种免疫应答的高、中或低风险(即,
拒绝),以及B)将低风险类别识别为可能耐受CNI最小化/撤销的那些。基于
根据这些数据,FDA接受HLA-DR/DQ mMM进入其生物标志物鉴定程序,
需要进行前瞻性多中心验证。为此,我们提出了一个前瞻性的观察,
一项多中心HLA mMM验证研究(Aim 1),在300例免疫静止患者的亚组中,
一项用抗IL-6 mAb(克拉扎珠单抗[Claza])替代CNI(目标2)的随机对照试验,
干预对2年结果的影响。机制研究将描绘出克拉扎
影响CNI替代后的结果。在这个框架内,我们将测试假设,在没有
在既存DSA中,HLA-DR/DQ mMM评分是一种预后和预测生物标志物,能够
指导肾移植中的免疫抑制治疗。此外,我们的财团已经确定了多个
亚临床/临床排斥的非侵入性诊断生物标志物。在目标3中,我们将:a)验证每个
单独和一起作为非侵入性诊断测试用于检测真实世界肾脏中排斥的生物标记
移植群组,和B)评估每种生物标志物检测响应于移植物的排斥的消退的效用,
通过治疗后活检确定的治疗。本R34提案的目标是完成研究
方案设计,完成机制研究设计,最终确定统计分析计划,并建立
试验操作和管理框架,以便能够提交FDA试验IND申请,
IRB批准的最终申请和U 01申请。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Peter Scott Heeger其他文献
Peter Scott Heeger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Peter Scott Heeger', 18)}}的其他基金
Assessment of Biomarker Guided CNI Substitution in Kidney Transplantation
肾移植中生物标志物引导的 CNI 替代评估
- 批准号:
10654057 - 财政年份:2022
- 资助金额:
$ 20.71万 - 项目类别:
Assessment of Biomarker Guided CNI Substitution in Kidney Transplantation
肾移植中生物标志物引导的 CNI 替代评估
- 批准号:
10488428 - 财政年份:2022
- 资助金额:
$ 20.71万 - 项目类别:
Multiparametric mapping of Covid-19 immune responses in Kidney transplant recipients
肾移植受者 Covid-19 免疫反应的多参数绘图
- 批准号:
10241179 - 财政年份:2020
- 资助金额:
$ 20.71万 - 项目类别:
Cell Death Pathways and Heart Transplant Rejection
细胞死亡途径和心脏移植排斥
- 批准号:
10162490 - 财政年份:2017
- 资助金额:
$ 20.71万 - 项目类别:
Targeting factor B to prevent transplant rejection
靶向因子 B 预防移植排斥
- 批准号:
9000104 - 财政年份:2015
- 资助金额:
$ 20.71万 - 项目类别:
Targeting factor B to prevent transplant rejection
靶向因子 B 预防移植排斥
- 批准号:
8873752 - 财政年份:2015
- 资助金额:
$ 20.71万 - 项目类别:
Individualizing Therapy for Kidney and Heart Transplant Recipients
肾脏和心脏移植受者的个体化治疗
- 批准号:
8100584 - 财政年份:2010
- 资助金额:
$ 20.71万 - 项目类别:
Noninvasive Markers and Transplant Outcome in Humans
人类非侵入性标志物和移植结果
- 批准号:
7919132 - 财政年份:2009
- 资助金额:
$ 20.71万 - 项目类别:
Cross-Disciplinary Training Program in Transplant Research
移植研究跨学科培训计划
- 批准号:
8662683 - 财政年份:2008
- 资助金额:
$ 20.71万 - 项目类别:
Cross-Disciplinary Training Program in Transplant Research
移植研究跨学科培训计划
- 批准号:
9284372 - 财政年份:2008
- 资助金额:
$ 20.71万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 20.71万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 20.71万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 20.71万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 20.71万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 20.71万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 20.71万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 20.71万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 20.71万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 20.71万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 20.71万 - 项目类别:
Research Grant